Scholarlink

<p>Among the emerging issues in probiotic safety, the possible presence of <i>pks</i>, a gene cluster synthetizing a genotoxin known as colibactin, is one of the most alarming. Indeed, indigenous <i>E. coli</i> strain <i>pks</i>-positive are found in 60% of patients with colorectal cancer, and the most widely used <i>E. coli</i>-based probiotic, known as <i>E. coli</i> Nissle 1917 (DSM 6601), is <i>pks</i>-positive. Starting from 25 potential candidates selected by screening 25 infant stool samples, we have selected an <i>E. coli</i> strain (named 5C, deposited as LMG S-33222) belonging to the phylotype A and having the serovar O173:H1. Having been previously completely sequenced by our group, we have further characterized this strain, demonstrating that it is (i) devoid of the most known potential pathogenic-related genes, (ii) devoid of possible plasmids, (iii) antibiotic-sensitive according to the EFSA panel, (iv) resistant in gastric and enteric juice, (v) significantly producing acetate, (vi) poorly producing histamine, (vii) endowed with a significant in vitro antipathogenic profile, (viii) promoting a significant in vitro immunological response based on IL-10 and IL-12, and (ix) devoid of the <i>pks</i> genes. A comparative genomics versus <i>E. coli</i> Nissle 1917 is also provided. Considering that the other two most commonly used <i>E. coli</i>-based probiotics (<i>E. coli</i> DSM 17252 and <i>E. coli</i> A0 34/86) are respectively <i>pks</i>-positive and alpha-hemolysin-(<i>hly</i>) and cytotoxic necrotizing factor-1-(<i>cnf1</i>) positive, this novel strain (<i>E. coli</i> 5C) is likely the probiotic <i>E. coli</i> strain with the best safety profile available to date for human use.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Selection, Comparative Genomics, and Potential Probiotic Features of Escherichia coli 5C, a pks-Negative Strain Isolated from Healthy Infant Donor Feces

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月16日

查看全文
  • Francesco Di Pierro,
  • Valeria Sagheddu,
  • Serena Galletti,
  • Alice Casaroli,
  • Edoardo Labrini,
  • Sara Soldi,
  • Massimiliano Cazzaniga,
  • Alexander Bertuccioli,
  • Mariarosaria Matera,
  • Ilaria Cavecchia,
  • Chiara Maria Palazzi,
  • Maria Laura Tanda,
  • Nicola Zerbinati

摘要

Among the emerging issues in probiotic safety, the possible presence of pks, a gene cluster synthetizing a genotoxin known as colibactin, is one of the most alarming. Indeed, indigenous E. coli strain pks-positive are found in 60% of patients with colorectal cancer, and the most widely used E. coli-based probiotic, known as E. coli Nissle 1917 (DSM 6601), is pks-positive. Starting from 25 potential candidates selected by screening 25 infant stool samples, we have selected an E. coli strain (named 5C, deposited as LMG S-33222) belonging to the phylotype A and having the serovar O173:H1. Having been previously completely sequenced by our group, we have further characterized this strain, demonstrating that it is (i) devoid of the most known potential pathogenic-related genes, (ii) devoid of possible plasmids, (iii) antibiotic-sensitive according to the EFSA panel, (iv) resistant in gastric and enteric juice, (v) significantly producing acetate, (vi) poorly producing histamine, (vii) endowed with a significant in vitro antipathogenic profile, (viii) promoting a significant in vitro immunological response based on IL-10 and IL-12, and (ix) devoid of the pks genes. A comparative genomics versus E. coli Nissle 1917 is also provided. Considering that the other two most commonly used E. coli-based probiotics (E. coli DSM 17252 and E. coli A0 34/86) are respectively pks-positive and alpha-hemolysin-(hly) and cytotoxic necrotizing factor-1-(cnf1) positive, this novel strain (E. coli 5C) is likely the probiotic E. coli strain with the best safety profile available to date for human use.